JPWO2022270585A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022270585A5 JPWO2022270585A5 JP2023530119A JP2023530119A JPWO2022270585A5 JP WO2022270585 A5 JPWO2022270585 A5 JP WO2022270585A5 JP 2023530119 A JP2023530119 A JP 2023530119A JP 2023530119 A JP2023530119 A JP 2023530119A JP WO2022270585 A5 JPWO2022270585 A5 JP WO2022270585A5
- Authority
- JP
- Japan
- Prior art keywords
- base sequence
- seq
- oligomer comprises
- unit
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021104145 | 2021-06-23 | ||
| PCT/JP2022/025120 WO2022270585A1 (ja) | 2021-06-23 | 2022-06-23 | アンチセンスオリゴマーの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022270585A1 JPWO2022270585A1 (https=) | 2022-12-29 |
| JPWO2022270585A5 true JPWO2022270585A5 (https=) | 2025-06-30 |
Family
ID=84544436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530119A Pending JPWO2022270585A1 (https=) | 2021-06-23 | 2022-06-23 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240301416A1 (https=) |
| EP (1) | EP4361269A4 (https=) |
| JP (1) | JPWO2022270585A1 (https=) |
| KR (1) | KR20240024176A (https=) |
| CN (1) | CN117940564A (https=) |
| AU (1) | AU2022298028A1 (https=) |
| BR (1) | BR112023027298A2 (https=) |
| CA (1) | CA3224782A1 (https=) |
| CO (1) | CO2023016805A2 (https=) |
| IL (1) | IL309626A (https=) |
| MX (1) | MX2023014417A (https=) |
| TW (1) | TW202307208A (https=) |
| WO (1) | WO2022270585A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| US20250121085A1 (en) * | 2023-10-02 | 2025-04-17 | Avidity Biosciences, Inc. | Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 45 skipping |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU655164B2 (en) | 1989-12-20 | 1994-12-08 | Antivirals Inc. | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| JP2924179B2 (ja) | 1993-02-19 | 1999-07-26 | 日本新薬株式会社 | グリセロール誘導体，デバイス及び医薬組成物 |
| US20060058253A1 (en) * | 2002-08-12 | 2006-03-16 | Benoit Chabot | Methods to reprogram splice site selection in pre-messenger rnas |
| EP2392660A3 (en) | 2002-11-25 | 2012-03-28 | Masafumi Matsuo | ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor |
| AU2003225410A1 (en) * | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| EP2933332A1 (en) | 2004-06-28 | 2015-10-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| PL2735568T3 (pl) | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| RU2606627C2 (ru) | 2007-11-15 | 2017-01-10 | Серепта Терапьютикс,Инк. | Способ синтеза морфолиновых олигомеров |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| JP5858285B2 (ja) | 2009-07-29 | 2016-02-10 | 東亞合成株式会社 | キャリアペプチドフラグメント及びその利用 |
| TR201816523T4 (tr) | 2009-11-12 | 2018-11-21 | Univ Western Australia | Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler. |
| CA3092114A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CA2861247C (en) | 2011-12-28 | 2021-11-16 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acids |
| EP2870246B1 (en) | 2012-07-03 | 2019-09-11 | BioMarin Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| AU2016264471B2 (en) | 2015-05-19 | 2022-01-27 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| HUE050061T2 (hu) * | 2015-09-15 | 2020-12-28 | Nippon Shinyaku Co Ltd | Antiszensz nukleinsav |
| JP2019525742A (ja) * | 2016-06-30 | 2019-09-12 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
| KR102810425B1 (ko) | 2016-12-19 | 2025-05-21 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| KR20240006023A (ko) | 2016-12-19 | 2024-01-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| PT3554552T (pt) | 2016-12-19 | 2022-10-03 | Sarepta Therapeutics Inc | Conjugados de oligómero de skipping de exão para distrofia muscular |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) * | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| CA3163608A1 (en) | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| JP7780691B2 (ja) | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| MX2023000984A (es) | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| CN116194470B (zh) | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| JP7041853B1 (ja) | 2020-09-14 | 2022-03-25 | 東亞合成株式会社 | キャリアペプチドフラグメントおよびその利用 |
-
2022
- 2022-06-23 WO PCT/JP2022/025120 patent/WO2022270585A1/ja not_active Ceased
- 2022-06-23 KR KR1020247000786A patent/KR20240024176A/ko active Pending
- 2022-06-23 JP JP2023530119A patent/JPWO2022270585A1/ja active Pending
- 2022-06-23 CN CN202280044513.5A patent/CN117940564A/zh active Pending
- 2022-06-23 MX MX2023014417A patent/MX2023014417A/es unknown
- 2022-06-23 TW TW111123470A patent/TW202307208A/zh unknown
- 2022-06-23 EP EP22828501.1A patent/EP4361269A4/en active Pending
- 2022-06-23 BR BR112023027298A patent/BR112023027298A2/pt unknown
- 2022-06-23 IL IL309626A patent/IL309626A/en unknown
- 2022-06-23 US US18/570,778 patent/US20240301416A1/en active Pending
- 2022-06-23 AU AU2022298028A patent/AU2022298028A1/en active Pending
- 2022-06-23 CA CA3224782A patent/CA3224782A1/en active Pending
-
2023
- 2023-12-04 CO CONC2023/0016805A patent/CO2023016805A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022270585A5 (https=) | ||
| AU2016202220B2 (en) | Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome | |
| JP2020039364A (ja) | キメラ２重鎖核酸 | |
| JP2022545118A5 (https=) | ||
| JP2019214587A5 (https=) | ||
| JP2021533804A5 (https=) | ||
| JP2022528487A5 (https=) | ||
| FI3673080T3 (fi) | Antisense-oligomeerejä häiriötilojen ja sairauksien hoitoon | |
| JPH08510900A (ja) | 改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド | |
| JP2022518929A5 (https=) | ||
| JP2020503070A (ja) | α−１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。 | |
| JP2001500511A (ja) | 修飾ＣｐＧジヌクレオシドを有するオリゴヌクレオチドの使用方法 | |
| JP7188804B2 (ja) | ジストロフィー型表皮水疱症を処置するためのアンチセンスオリゴヌクレオチド | |
| JP2024020326A (ja) | 一本鎖オリゴヌクレオチド | |
| JP2022520986A5 (https=) | ||
| JP2024112834A5 (https=) | ||
| KR20200024793A (ko) | 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법 | |
| JPWO2021125311A5 (https=) | ||
| TWI868323B (zh) | 誘導外顯子５１跳讀的反義核酸 | |
| JP2019527549A (ja) | 転写プロセシングの調節のための化合物及び方法 | |
| CN118019848A (zh) | Rna编辑 | |
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JPH09104629A (ja) | ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤 | |
| CA3269248A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS | |
| BR112020022519A2 (pt) | usos e métodos terapêuticos |